Fig. 3.

SARS-CoV-2 antibody concentrations after first vaccine dose in XLA patients on continuous immunoglobulin replacement therapy. A Four healthy controls and B four XLA patients were given the first and second doses of mRNA BNT162b2 vaccine against SARS-CoV-2 on days 0 and 21, respectively. All had an additional dose before their final plotted value. Anti-spike antibody levels were determined using the Phadia system except for XLA2 day 327 and XLA4 day 344 for which the Thermo system was used. PCR-positive COVID-19 (C19) in the XLA patients is indicated using the corresponding color. XLA1 had been treated with SARS-CoV-2-specific monoclonal antibodies (Regeneron) before the antibody assessment on day 196. HC healthy control, XLA X-linked agammaglobulinemia